The company moved to solid profitability, with 2025 net income of $287.2 million versus $5.8 million a year earlier. A collaboration with Otsuka Pharmaceutical Co., Ltd. has allowed Aurinia to extend its market presence to Japan, the E.U., the U.K., and Switzerland, diversifying revenue streams and mitigating single-market risk. However, Aurinia's dependence on LUPKYNIS for the majority of its revenue exposes the company to market volatility and competitive pressures, as any challenges could have a disproportionate impact on financial performance.
Cyborg Score Rationale
Net income jumped to $287.2M on $283.1M revenue as LUPKYNIS sales grew 25%. Cash from operating activities jumped to $135.7 million, supporting the quality of results. Strong commercial execution and profitability achievement are offset by single-product dependency and modest pipeline activity.
Top Insights
Sales of flagship lupus nephritis medicine Lupkynis increased 29% year over year to $74.2 million in Q4 2025 and 25% for the full year.
For 2026, Aurinia guides to total revenue of $315–$325 million and LUPKYNIS net product sales of $305–$315 million, implying low- to mid-teens percentage growth.
The company's decision to repurchase 12.2 million common shares for $98.2 million signals confidence in future prospects and commitment to shareholder value.
Aurinia is also developing aritinercept (AUR200) for the potential treatment of autoimmune diseases.
Named Competitors
Lupus Nephritis Therapies (Various) — Traditional immunosuppressants and competing lupus treatments
AUR200 — Dual inhibitor in development for broader autoimmune disease applications
Recent Developments
(February 2026) Strong Q4 2025 results: net income $287.2M, total revenue $283.1M, LUPKYNIS sales grew 25% to $271.3M annual; raised 2026 guidance
(2025) Completed share repurchase of 12.2 million shares for $98.2 million; ended year with $398M in cash and investments
(Ongoing) International expansion through Otsuka partnership extending to Japan, EU, UK, and Switzerland
Open the full interactive Aurinia Pharmaceuticals Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.